Beta Bionics and the promise of autonomy
A simpler diabetes tech is in the offing, but some patients are yet to be convinced that a device knows best.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Philips draws a line under its sleep nightmare
The group has finally revalued its troubled sleep franchise. So what now?
TCT 2022 – Otsuka’s renal denervation system shines
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
Medtech takes on pain
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
Medtech research spending set to slow in 2022
And some diagnostics groups are forecast to actually cut R&D outlay this year as the pandemic eases.
Up-and-down test sales and a bigger Medtronic: medtech in 2028
Medtronic, Siemens and Stryker are all expected to seize greater market share, while Roche slides down the rankings.
